Nissen fundoplication decreases the use of antireflux medications.
Retrospective cohort study using discharge abstract data and pharmacy data.
Twelve regional Kaiser Permanente hospitals in southern California.
Three hundred forty-two patients underwent Nissen fundoplication.
Main Outcome Measure
Use of antireflux medications.
The number of patients requiring antireflux medications decreased from 233 patients (68.1%) before Nissen fundoplication to 197 (57.6%) after Nissen fundoplication. Of the 233 patients, 176 (75.6%) were restarted on antireflux medications within 1 year after Nissen fundoplication. Use of antireflux medication decreased in neurologically healthy patients but was unchanged in neurologically impaired children.
Use of antireflux medication decreased after Nissen fundoplication. Neurologically healthy children showed the biggest decrease in antireflux medication use after Nissen fundoplication.
Gastroesophageal reflux, or physiological reflux, is common in infants and children. Although the natural history of gastroesophageal reflux is not well understood, most children will outgrow their symptoms by 12 to 18 months of age.1 Gastroesophageal reflux disease (GERD), on the other hand, is pathological and requires treatment to prevent associated complications of reflux esophagitis, Barrett esophagus, and esophageal stricture. Medical management remains the mainstay of treatment for GERD and is successful in most patients. Gastroesophageal reflux disease may also be associated with pulmonary complications, apnea, and failure to thrive, and this is when antireflux operations are generally considered. With the introduction of minimally invasive techniques, laparoscopic Nissen fundoplication (NF) has been performed with increased frequency during the last decade and is now one of the most common operations performed by pediatric surgeons, with more than 30 000 antireflux operations performed annually.2 Successful NF may also obviate the inconvenience and expense of lifelong medical management.
The long-term effect of NF remains controversial. Excellent symptomatic results following NF have been shown in large retrospective studies.3- 4 However, objective long-term data following NF in children are not available. Furthermore, studies in adults have shown a high rate of relapse in patients with severe GERD following NF, with a significant number of patients requiring antireflux medications.5 The purpose of this study is to determine whether NF decreases the use of antireflux medications in children.
The Southern California Kaiser Permanente Discharge Abstract Database was used to identify pediatric patients (aged < 19 years) hospitalized in 12 acute care hospitals for NF for GERD between January 1, 1996, and December 31, 2005. Surgical therapy was determined according to the Current Procedural Terminology, 4th Edition procedure code for NF. This study was approved by the institutional review board of Kaiser Permanente Southern California, protocol numbers 3934 and 5040.
Data of patients were then analyzed using the Southern California Kaiser Permanente Pharmacy Database for use of antireflux medications. Specifically, use of H2-blockers and proton pump inhibitors was analyzed. The pre-NF period was defined as birth to the first NF, and the post-NF period was defined as the time from the first NF to death or to the end of the study, whichever came first. The number of patients using antireflux medications was recorded before and after NF.
The data from the Southern California Kaiser Permanente Discharge Abstract Database were exported to SAS version 9.13 statistical software (SAS Institute Inc, Cary, North Carolina) for subsequent analyses. Use of antireflux medication before and after NF was analyzed using the McNemar test. Odds ratios were calculated using logistic regression. In addition to NF, underlying neurological disorder was also included in the regression model. Estimates were considered statistically significant if the 95% confidence interval did not overlap 1.00 and if P < .05.
A total of 342 patients were identified as having an NF during the study period. The mean (SD) age at the time of NF was 3.9 (4.8) years (median age, 1 year; age range, 0-17 years). The male to female ratio was 1.19 to 1. The mean follow-up was 4.5 years. A total of 154 patients (45.0%) had an associated neurological disorder. Twenty-six patients (7.6%) had more than 1 NF performed.
Medication data were available in 336 patients. A total of 233 patients were administered antireflux medication prior to NF and 197 patients were administered antireflux medication after NF (Table 1) (odds ratio = 0.63; 95% confidence interval, 0.47-0.84; P = .002). Of the 233 patients receiving antireflux medication prior to NF, 150 were restarted on antireflux medication after NF. An additional 47 patients with no history of antireflux medication use were started on antireflux medication after NF. Of the 233 patients, 176 (75.6%) were restarted on antireflux medications within 1 year after NF. Use of antireflux medication decreased in neurologically healthy patients, but there was no significant change in neurologically impaired children (Table 2).
The goals of an antireflux operation are to relieve reflux symptoms, decrease GERD-related complications and hospitalizations, and halt the use of antireflux medications. Previous studies have shown that antireflux procedures are successful in relieving reflux symptoms in children.4 In a multi-institutional review of 7467 patients, Fonkalsrud et al4 reported good to excellent resolution of symptoms in 95% of neurologically healthy children and 85% resolution in neurologically impaired children after NF. However, these subjective outcomes were not clearly defined and there were no objective outcome measures in this study. Furthermore, follow-up was based on a questionnaire filled out by each of the participating institutions rather than on objective evaluation of the patient. For these reasons, the methods and results of this study have been questioned.
In the experience of 1050 pediatric NFs by a single surgeon at a single institution, the recurrence rate after laparoscopic NF was reported to be 3.1%.3 This remarkable study showed that laparoscopic NF can be safely performed in children as young as 5 days and as small as 1.2 kg. This study, however, did not provide details of the follow-up; it appears that the only objective follow-up was reoperation. Thus, this study showed that laparoscopic NF can be done in children but did not answer the questions of whether NF should be done and in whom NF should be done.
Few studies have documented objective end points following NF in children. Conversely, in adult patients, long-term follow-up comparing medical and surgical management of GERD showed no difference in grade of esophagitis, frequency of treatment of esophageal stricture, 36-Item Short Form Health Survey scores, and overall satisfaction with antireflux therapy.5 Such end points following NF are difficult to reproduce in children. Not all children being treated for GERD routinely undergo endoscopy to document esophagitis or stricture. Furthermore, existing quality-of-life surveys used in adults are not applicable to children. Currently, quality-of-life tools are being developed and validated specifically for caregivers of children with GERD and may be more accurate than symptoms and perceived satisfaction following NF.6 Finally, the preoperative evaluation for children undergoing NF is inconsistent, making it difficult to accurately assess the effect following NF. One reason for such an inconsistent preoperative workup is that the diagnosis of GERD and current indications for NF are mostly based on clinical factors. Nissen fundoplication is often performed in pediatric patients with associated pulmonary symptoms such as pneumonia, respiratory distress, and apnea. It has also been advocated for children with failure to thrive despite medical management. Many believe that NF is warranted in children with such significant GERD-related complications and that an extensive preoperative evaluation would only delay and not change management.
We previously looked at the number of hospitalizations for GERD-related complications to determine long-term effectiveness following NF. There was no change in the frequency of hospitalizations, the number of hospitalizations, or the number of patients hospitalized for pulmonary symptoms and failure to thrive before and after NF.7 One surprising finding was that there were a significant number of patients requiring hospitalization for GERD-related complications who had no history of hospitalization prior to NF. However, in those patients with a well-documented GERD-related complication prior to NF, it appears that NF may decrease future hospitalizations for that specific complication. This finding emphasizes the need for a standard preoperative evaluation for GERD. This may help to identify which children are at risk for developing recurrent symptoms or postoperative hospitalizations for GERD-related complications and would benefit most from NF. Goldin et al8 recently demonstrated mixed results in a population-based study looking at the frequency of hospitalizations for GERD-related complications. The frequency of hospitalizations decreased in children younger than 4 years, did not change in older children, and increased in older children with developmental delay.
To our knowledge, no studies have compared medical management with surgical management of GERD in children. Furthermore, long-term outcomes studies following medical management of GERD in children are not available. Proton pump inhibitors are highly efficacious in treating GERD in children.9 However, long-term safety data for children do not exist. To date, the longest-term safety and efficacy data in children for continuous use of proton pump inhibitors are for 2 years.9 One potential benefit of NF may be to eliminate the use of antireflux medications. Our study showed that long-term use of antireflux medication following NF decreased by 37.0%. Most children (176 of 233 children [75.6%]) required readministration of antireflux medications within 1 year of NF. Thus, NF should not be performed with the expectation that patients will no longer need antireflux medications. An unexpected finding of our study is that only 233 patients (68.1%) were receiving antireflux medications prior to NF. This result likely represents the era in which it was believed that NF should be performed in patients perceived as having a high risk of developing GERD or GERD-related complications, most notably in patients with underlying neurological disorders. More specifically, there is currently very little evidence to support performing NF in children with neurological disorders who are undergoing gastrostomy tube placement.
Patients with underlying neurological disorders have a higher complication rate following NF.10 This includes a higher reoperation rate for wrap disruption in neurologically impaired children.10- 12 Previous studies7- 8 have also shown that patients with associated neurological disorders have an increased risk of hospitalization for GERD-related complications following NF. Our study showed that use of antireflux medications in patients with underlying neurological disorders did not change following NF. Thus, the severity of GERD, recurrence of GERD-related complications, and antireflux medication use following NF may be more affected by a patient's underlying neurological status than by performing NF.
Our study has several limitations. Our data come from a discharge abstract database, and the International Classification of Diseases, Ninth Revision or Current Procedural Terminology, 4th Edition coding of each diagnosis and procedure was not independently validated. Thus, we were not able to determine the exact indications for NF. Some patients with underlying neurological or cardiac anomalies had NF performed based on their perceived risk of developing GERD. Also, technical details of the NF such as the length of wrap, crural approximation, or open vs laparoscopic were not available. Another limitation of this study is that indications for administration of antireflux medications were not reviewed and are not known. Previous studies13- 14 have shown that antireflux medications may be overprescribed in children. Antireflux medications were prescribed without adequate workup and documented GERD. In adult studies, up to 80% of patients were still receiving antireflux medication following NF.15 However, other adult studies have shown that only one-fourth of patients receiving acid suppression medication after NF had abnormal pH study results.16- 17 In our study, we do not know who (pediatricians, pediatric surgeons, pediatric gastroenterologists, etc) restarted the patients on antireflux medications, nor do we know whether such medications were actually discontinued following NF. It has been our practice, however, to wean patients off of all antireflux medications starting 3 to 4 weeks after NF. Lastly, we do not know how compliant patients were in using the antireflux medications. Our pharmacy database represents dispensed medications, so we cannot be sure that the patients were using what was prescribed.
Overall, the findings of this study demonstrated a slight decrease in antireflux medication use after NF. In children with neurological impairment, there was no decrease in antireflux medication use after NF. We strongly advocate standardizing the preoperative evaluation prior to any antireflux procedure as this may better select which children are at highest risk for recurrent GERD requiring antireflux medications. Since implementing a more thorough preoperative workup for GERD, we have noticed a significant decrease in the number of NFs performed at our institution. Finally, to prevent overprescribing acid suppression medication after NF, the diagnosis of GERD should be confirmed when restarting medical management.
Correspondence: Steven L. Lee, MD, Division of Pediatric Surgery, Kaiser Permanente, Los Angeles Medical Center, 4760 Sunset Blvd, Third Floor, Los Angeles, CA 90027 (email@example.com).
Accepted for Publication: April 7, 2008.
Author Contributions:Study concept and design: Lee and Applebaum. Acquisition of data: Lee. Analysis and interpretation of data: Lee, Sydorak, Chiu, Hsu, Applebaum, and Haigh. Drafting of the manuscript: Lee. Critical revision of the manuscript for important intellectual content: Lee, Sydorak, Chiu, Hsu, Applebaum, and Haigh. Statistical analysis: Sydorak, Chiu, Hsu, and Haigh. Administrative, technical, and material support: Applebaum. Study supervision: Lee and Sydorak.
Financial Disclosure: None reported.
Previous Presentation: This paper was presented at the 79th Annual Meeting of the Pacific Coast Surgical Association; February 17, 2008; San Diego, California; and is published after peer review and revision. The discussions that follow this article are based on the originally submitted manuscript and not the revised manuscript.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and
Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early
dhildhood mortality and growth failure data and their association with maternal
Thank you for submitting a comment on this article. It will be reviewed by JAMA Surgery editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 4
Customize your page view by dragging & repositioning the boxes below.
Figure 22.1-2. Cost-effectiveness Plane and Sensitivity Analysis on Price of H2RAs
Figure 22.1-3. Probabilistic Sensitivity Analysis and Cost-effectiveness Acceptability Curves...
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.